Compared to patients without ASXL1 mutations, ASXL1mut patients tended to be associated with worse OS in the cohort (median OS, 31 vs. 67 months, p = 0.23; Figure 5B) and in the MDS‐LB subgroup (median OS, not reached, p = 0.34; Figure 5C), but not in the MDS‐IB subgroup (median OS, 31 vs. 12 months, p = 0.78; Figure 5D). This evidence concerns the gene ASXL1 and myelodysplastic syndrome.